The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Michael E. Nassif, Mikhail Kosiborod, Sanjiv J. Shah et al.|Nature Medicine|2021

Cited by 599